Avalo Therapeutics Inc. has released a corporate presentation highlighting their development of targeted therapies for immune-mediated inflammatory diseases. The lead compound, AVTX-009, an anti-IL-1β monoclonal antibody, is positioned as a potential "best-in-disease" therapy for hidradenitis suppurativa (HS). The company emphasizes AVTX-009's higher affinity and longer half-life compared to lutikizumab, suggesting potential for greater efficacy and more convenient dosing. The Phase 2 LOTUS trial for AVTX-009 in HS has commenced, with topline data anticipated by mid-2026. Avalo also indicates a cash runway extending into at least 2027. The HS market is projected to exceed $10 billion by 2035. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。